Literature DB >> 7785941

Screening for drugs of abuse. I: Opiates, amphetamines and cocaine.

R A Braithwaite1, D R Jarvie, P S Minty, D Simpson, B Widdop.   

Abstract

(1) In order to provide an efficient and reliable service for drugs of abuse screening in urine, the laboratory should analyse 20-30 samples per week, and the staff should include a scientist with special expertise in the subject. (2) Turnaround times should be between 2-3 days of sample collection. To achieve this aim it may be necessary to make special arrangements for the delivery of samples to the laboratory. Results should preferably be transmitted by electronic mail or facsimile with the necessary precautions for security and confidentiality: hardcopy reports may also be required. (3) Good communications between the requesting clinician and the laboratory are essential. An advisory service should be provided by the laboratory and clinicians should be encouraged to discuss requests and results with laboratory staff. It is important that the laboratory inform doctors of the range of substances detected and the sensitivity and specificity of laboratory assays. (4) Assays should be performed according to the manufacturer's protocols, or by modified methods that have been rigorously validated. Quality control samples should be included in each analytical run and participation in an external quality assessment scheme, e.g. UKNEQAS, is essential to provide independent confirmation and confidence that results compare with those from other laboratories. Other requirements include adequate training and supervision of staff, and careful recording of samples and results. (5) Drugs to be tested will depend on the drug 'scene' in the area but should include those drugs regularly prescribed for maintenance therapy (e.g. methadone, dihydrocodeine, benzodiazepines), and drugs frequently misused (e.g. heroin, buprenorphine, amphetamines, cocaine). (6) Positive results obtained by preliminary screening methods e.g. EMIT, should be confirmed by another analytical technique, e.g. TLC, GC or GC-MS. If there are potentially serious or legal implications, and in employment and preemployment testing, confirmation of positive results is mandatory. In some cases, e.g. checking for methadone or benzodiazepine compliance, it may be considered unnecessary to confirm positive results although possible spiking of samples cannot be excluded without checking for the presence of metabolites by a chromatographic procedure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785941     DOI: 10.1177/000456329503200203

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  5 in total

1.  Detection of drug misuse--an addictive challenge.

Authors:  J H Galloway; I D Marsh
Journal:  J Clin Pathol       Date:  1999-10       Impact factor: 3.411

Review 2.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

3.  Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.

Authors:  Roger Chou; Gilbert J Fanciullo; Perry G Fine; Jeremy A Adler; Jane C Ballantyne; Pamela Davies; Marilee I Donovan; David A Fishbain; Kathy M Foley; Jeffrey Fudin; Aaron M Gilson; Alexander Kelter; Alexander Mauskop; Patrick G O'Connor; Steven D Passik; Gavril W Pasternak; Russell K Portenoy; Ben A Rich; Richard G Roberts; Knox H Todd; Christine Miaskowski
Journal:  J Pain       Date:  2009-02       Impact factor: 5.820

Review 4.  Practical guide to the management of acute and chronic pain in the presence of drug tolerance for the healthcare practitioner.

Authors:  Nalini Vadivelu; Harman Singh-Gill; Gopal Kodumudi; Aaron Joshua Kaye; Richard D Urman; Alan David Kaye
Journal:  Ochsner J       Date:  2014

Review 5.  Novel technologies in detection, treatment and prevention of substance use disorders.

Authors:  Hichem Moulahoum; Figen Zihnioglu; Suna Timur; Hakan Coskunol
Journal:  J Food Drug Anal       Date:  2018-09-28       Impact factor: 6.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.